OUTMANEUVERING THE WORLD

Syntera Automations is a pharmaceutical innovation and licensing company focused on advancing differentiated, formulation-driven therapeutics through regulatory-efficient development and global out-licensing. We specialize in PEGylated, microsphere, and nanoformulated injectables targeting cachexia, metabolic disorders, neuroinflammation, and addiction—addressing high-need, underdeveloped treatment areas.

Our approach is lean but rigorous: we develop IND-ready and licensing-stage assets using PBPK simulation, bridging literature, and targeted preclinical data. We strategically deploy traditional GLP-grade toxicology and pharmacokinetic studies when they enhance asset value and accelerate partner readiness—never when they obstruct speed or strategic clarity.

Each Syntera asset is purpose-built for licensing under 505(b)(2) and international equivalents, with clear IP positioning, novel mechanisms of action, and formulation science tailored to clinical realities. Our development platform emphasizes speed, ethical innovation, and global scalability.

At Syntera Automations, we don’t just formulate treatments—we position them for impact.

Social Therapeutics

Social Therapeutics refers to the intentional design and deployment of therapeutic innovations that not only treat biological conditions but also address the structural, social, and access-based inequities in global healthcare. At Syntera, this means developing formulation-based pharmaceuticals that are:

  • Regulatory-efficient, allowing faster entry into markets where clinical trial infrastructure is limited

  • Clinically appropriate, targeting conditions disproportionately affecting underserved or overlooked populations (e.g., cachexia in late-stage cancer, metabolic disorders in low-income regions)

  • Affordable to license and scale, ensuring regional partners can bring therapies to market without excessive commercialization or data burdens

  • Engineered for real-world use, including long-acting, multi-API injectables that reduce dependence on daily adherence or cold-chain storage

At its core, Social Therapeutics bridges scientific advancement with public health impact—anchoring pharmaceutical innovation in inclusion, accessibility, and system-level change.

Social Therapeutics

Ask What This Means and How You Can Be Apart!

About Syntera

The Syntera Origin Story

Syntera was founded with a singular purpose: to close the gap between scientific innovation and real-world impact. After years of hands-on experience in healthcare delivery and systems management, Jamie Gray recognized a critical disconnect—life-saving therapies often stalled in development or overlooked entirely due to complexity, cost, or regulatory friction.

Determined to build a model that moves faster and serves broader, Jamie launched Syntera as a formulation-driven licensing platform—focused on regulatory efficiency, scientific precision, and market adaptability.

My Founder Story

"I didn’t start Syntera to follow convention. I started it because I saw how many critical treatments never make it to the people who need them.

There had to be a smarter, faster, and more accessible way to move therapies forward—one that values lean innovation, ethical development, and partnerships that scale. Syntera is that platform: focused, execution-driven, and built to deliver."

— Jamie Gray, RN, APNP-BC
Clinician | Founder & CEO, Syntera Automations

Solutions

Global Access for Underserved Therapeutic Areas

The Problem: Diseases like cachexia, neuroinflammation, and metabolic disorders remain underserved due to lack of investment, despite high clinical need.
Our Solution: We focus on these therapeutic gaps with differentiated, multi-API injectables that are optimized for regional licensing. Our science is designed for both efficacy and access—empowering local partners to bring high-impact therapies to market.

Lean, Ethical Advancement Without Overbuilding

The Problem: Pharma assets are often over-engineered, over-tested, and under-licensed—leading to waste and delay.
Our Solution: Syntera advances assets using the minimal effective data strategy—combining PBPK simulation, bridging literature, and targeted preclinical work. We add traditional GLP studies only when it strengthens the license, not when it slows the mission.

Ethical Innovation Without Unnecessary Animal Testing

The Problem: Traditional drug development often relies heavily on animal testing—even when modern alternatives exist—leading to ethical concerns and unnecessary delays.
Our Solution: Syntera is committed to minimizing animal use through a simulation-first development model. We leverage advanced PBPK modeling, literature bridging, and mechanistic validation to avoid early-stage animal studies unless they provide clear, value-adding insight.

When animal testing is necessary, we partner exclusively with GLP-aligned labs that adhere to the 3Rs: Replace, Reduce, Refine. Our mission is to balance speed, ethics, and scientific integrity—proving that life-saving medicine doesn't have to come at the cost of unnecessary animal suffering.

“Smart simulation isn't just efficient—it’s humane.”

Licensing-Ready Formulations Without the Wait

The Problem: Traditional drug development timelines are too long, too costly, and often stall before commercialization—especially for injectable therapeutics.
Our Solution: Syntera delivers fully developed, assignable formulations designed for fast-track regulatory pathways like 505(b)(2). We remove the R&D burden and provide simulation-supported, partner-ready assets with clear IP, MOA, and scalability.

How It Works

Select for Unmet Need & Social Impact

We begin with purpose. Syntera targets therapeutic gaps where existing treatments are inadequate, inaccessible, or carry high systemic burdens—such as cachexia, neuroinflammation, and metabolic disorders. We focus on diseases that affect vulnerable populations, where a single optimized injectable can dramatically improve outcomes and equity.

License with Global Equity in Mind

We license our assets to regional and global pharma partners committed to expanding access. Each deal is structured for commercial success and health equity—empowering our licensees to localize manufacturing, reduce patient burden, and bring forward science that serves, not excludes.

Engineer Regulatory-Efficient Formulations

We design PEGylated, microsphere, and nanoformulated injectables that are built for 505(b)(2) or equivalent global pathways. Our formulations prioritize long-acting delivery, combination APIs, and tolerability-enhancing adjuncts—reducing the need for high-cost clinical studies while preserving scientific rigor.

Validate Strategically, Ethically, and Fast

Our approach blends modern PBPK simulation, mechanistic literature, and targeted preclinical studies. We partner with GLP-aligned labs only when data is truly value-enhancing—ensuring rapid progression without unnecessary animal use or regulatory delay. Every study is aligned with our goal: fast, ethical, license-ready advancement.

Ready to License Smarter?

Explore formulation-ready assets built for speed, scale, and regulatory success.